Sinogene Biotechnology (Beijing, 2017-)
firmNations & Geopolitics · Biotech & Transhumanism
A Chinese company will clone your dead pet for tens of thousands of dollars, using a warehouse of 1,000 breeding dogs.
Who they are
Sinogene Biotechnology, a Beijing firm that launched commercial cloning in 2017.
What they do
It sells pet-cloning services to the public[1].
How it works
It has produced more than 500 pet clones at €20,000 to €60,000 each, running a base of over 1,000 laboratory beagles to serve as surrogate mothers; it operates outside US and EU rules, funded entirely by wealthy Chinese customers wanting their pets recreated.
Why it matters
That 1,000-dog surrogate operation is exactly the kind of large-scale biological manufacturing Western universities can't legally maintain, an example of doing business by locating where the rules don't apply, and it feeds the engine's theme of institutions competing across looser regulatory borders.
The engine's record — word for word
Launched commercial cloning services 2017. 500+ pet clones produced; maintains 1,000+ laboratory beagle breeding base for surrogate infrastructure. Per-canine clone cost €20,000-€60,000. Operates explicitly outside US/EU regulatory frameworks; entirely demand-driven by Chinese pet-humanization trends + high-net-worth capital. Engine framing: regulatory-arbitrage substrate node — physical infrastructure (surrogate breeding base of 1,000+ beagles) constitutes the kind of industrial-scale biological manufacturing capacity that Western academic research cannot legally maintain. Apex (b) Institutional-Competition load-bearing. [Bio-Bricks re-audit 2026-08] Wild-species SCNT milestone: Sinogene cloned the world's FIRST wild arctic wolf, 'Maya,' born 10 Jun 2022 (137 reconstructed embryos from enucleated oocytes + skin-cell donor; PRIMARY-VERIFIED, Global Times 2022) — SCNT maturing from pets to non-domesticated mammals.
Follow the trail
Walk this on the live map →